Table 2.
Blocking CD47-SIRPα axis Applied in OC.
| Treatment | Agent | Target | Model | Reference |
|---|---|---|---|---|
| Monotherapy | B6H12 | CD47 | SK-OV-3 OC Cell Lines | 46 |
| Anti-47 mAb | CD47 | TOV-112D and TOV-21G EAOC Cell Lines | 87 | |
| Anti-47 mAb | CD47 | Ovarian CSCs | 87 | |
| Hu5F9-G4 | CD47 | Ovarian/Fallopian Tube Cancer | 89,90 | |
| BI 765063 | SIRPα | OC | 121 | |
| AO-176 | CD47 | Epithelial Ovarian Carcinoma | 108–110 | |
| Combined with Tumor-targeting Antibodies/Adaptive ICIs | Hu5F9-G4 + Avelumab (PD-L1) | CD47+PD-L1 | Platinum-resistant/Refractory OC | 122 |
| Bispecific Antibodies | PF-07257876 | CD47+PD-L1 | OC | NCT04881045 |
| SL-172154 | SIRPα+CD40 L | NCT04406623116 | ||
| Other Combination Therapies | Anti-CD47 mAbs + Chemotherapy + Photodynamic Therapy | CD47 | Ovarian carcinoma OVCAR-3 cell Lines | 123 |
| Dual CAR-T Cells | CD47+TAG-72 | Ovarian carcinoma OVCAR-3 cell Lines | 124 | |
| OV-αCD47 | CD47 | OC Cell Line A2780 | 125 | |
| TTI-662+ PLD | CD47 | OC | NCT05261490 |
Abbreviations: CAR-T, chimeric antigen receptor T; OV, oncolytic virus; PLD, PEGylated liposomaldoxorubicin; TAG-72, tumor-associated glycoprotein 72.
The related references cited in Table 2 can be found in Anonymous Main Document.